EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Neoadjuvant Therapy of Gastric Cancer: A Decisive Step Forward

Markus Menges, Thomas Hoehler

Gastrointestinal Tumors · 2014

DOI: 10.1159/000362577 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Gastrointestinal Tumors, 2014. Verfasst von Markus Menges und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine 2, Diakonie-Hospital, Schwäbisch Hall, Recklinghausen, Germany. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Although its incidence has been steadily decreasing in Western countries, gastric cancer remains a leading cause of cancer deaths worldwide. The detection rate of early-stage cancers is improving; nevertheless, the majority of cases is still diagnosed at later stages with a poor prognosis. Furthermore, the results that can be achieved with surgery have reached a plateau of effectiveness. Summary: Neoadjuvant chemotherapy was successfully introduced first in patients with non-curatively resectable disease. In the last decade, neoadjuvant chemotherapy has also been established in potentially curatively resectable cases and has become the state-of-the-art treatment. Esophagogastric junction (EGJ) tumors are not optimally treated with chemotherapy alone, and combined radiochemotherapy (RCT) seems to yield superior outcomes. Key Message: The use of neoadjuvant therapy has been successfully established in patients with curatively resectable disease. Neoadjuvant chemotherapy is now a cornerstone in the treatment of gastric cancer and cancer of the EGJ, although further work is needed in order to define the optimal combination regimen. Practical Implications: Neoadjuvant chemotherapy is currently the gold standard for the treatment of gastric cancer and cancer of the EGJ. Several independent studies have shown the benefits of using combination regimens that included cisplatin and 5-fluorouracil, though recently the use of the EOX (epirubicin, oxaliplatin and capecitabine) regimen has been widely accepted in this setting. Tumors of the EGJ benefit from neoadjuvant treatment with combined RCT. It should be noted that the optimal neoadjuvant regimen in EGJ tumors has not yet been defined, and the survival advantage of neoadjuvant RCT over neoadjuvant chemotherapy remains to be established in this patient population.

Schlagwörter

Stichwörter der Autor:innen

Cancer of the esophagogastric junctionGastric cancerImprovement of prognosisNeoadjuvant chemotherapyNeoadjuvant radiochemotherapy

Autor:innen und Institutionen

  • Department of Internal Medicine 2, Diakonie-Hospital, Schwäbisch Hall, Recklinghausen, Germany.
  • Department of Internal Medicine 1, Prosper Hospital, Recklinghausen, Germany.

Zitieren

APA

Menges, M., & Hoehler, T. (2014). Neoadjuvant Therapy of Gastric Cancer: A Decisive Step Forward. Gastrointestinal Tumors. https://doi.org/10.1159/000362577

Vancouver

Menges M, Hoehler T. Neoadjuvant Therapy of Gastric Cancer: A Decisive Step Forward. Gastrointestinal Tumors. 2014. doi:10.1159/000362577

BibTeX
@article{Menges2014,
  author = {Menges, Markus and Hoehler, Thomas},
  title = {Neoadjuvant Therapy of Gastric Cancer: A Decisive Step Forward},
  journal = {Gastrointestinal Tumors},
  year = {2014},
  doi = {10.1159/000362577}
}
Kostenlos starten →